Bavarian Nordic mulls over expanding monkeypox vaccine production with partners

The Danish vaccine maker is in dialogs with potential partners that could step in for the filling of vials or the production of bulk vaccines, should it become necessary.

Bavarian Nordic is considering whether it will become necessary to find a partner to produce bulk vaccine of the company's monkeypox product | Photo: Bavarian Nordic / PR

Should the need to gear up the production of monkeypox vaccine doses increase, Bavarian Nordic is ready to expand by finding more partners, Danish daily Børsen reports.

On Monday, Bavarian signed a new deal with the Canadian government, revising an existing supply deal with the country concerning doses of the vaccine branded regionally as Imvanex, Jynneos, or Imvamune.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs